Medical Research News

RSS

PharPoint Research joins Medidata's ASPire to Win channel partner program

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.

10 Jan 2011

Celator, Cephalon extend cancer research agreement

Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

10 Jan 2011

95.6% of WTC survivors report posttraumatic stress symptoms

Nearly 10 years after the greatest human-made disaster in U.S. history-- the destruction of the World Trade Center (WTC) towers -- there has been little research documenting the attacks' consequences among those most directly affected -- the survivors who escaped the World Trade Center towers.

10 Jan 2011

Research suggests novel therapeutic approach for Huntington's Disease

Hope for new ways of treating devastating neurodegenerative disorders such as Huntington's disease has been raised by a trans-Atlantic team of researchers thanks to the use of cutting-edge genetic techniques.

10 Jan 2011

LabCorp to market On-Q-ity's circulating tumor cell platform

On-Q-ity, a next-generation oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, today announced a strategic alliance with Laboratory Corporation of America Holdings® (LabCorp). LabCorp will market On-Q-ity's novel and proprietary circulating tumor cell (CTC) platform to the biopharma industry to greatly accelerate and improve the cancer drug discovery and development process.

10 Jan 2011

Slowing engines of mitochondria could extend life

In making your pro-longevity resolutions, like drinking more red wine and maintaining a vibrant social network, here's one you likely forgot: dialing down your mitochondria. It turns out that slowing the engines of these tiny cellular factories could extend your life-an observation relevant not only to aging research but to our understanding of how cells communicate with each another.

10 Jan 2011

Quality of life measures most useful for clinical decision-making in trials with QOL as primary outcome

Quality of life measures tend to be most useful for clinical decision-making in trials in which quality of life is the primary outcome, according to a recent study published online January 7 in The Journal of the National Cancer Institute.

10 Jan 2011

Two signaling molecules communicate across nerve cells to regulate electrical, chemical activity: Study

In the Old West, camps sent smoke signals across distances to share key developments or strategy. Likewise, two important signaling molecules communicate across nerve cells to regulate electrical and chemical activity, neuroscientists from the UT Health Science Center San Antonio reported today.

10 Jan 2011

Researchers identify gene mutation for that is essential for correct protein-processing in cells

A Jackson Laboratory research team led by Professor Patsy Nishina, Ph.D., has identified a mutation in a gene that's essential for correct protein-processing in cells. Defects in protein folding are associated with a variety of abnormalities and diseases.

10 Jan 2011

Study finds link between nonalcoholic fatty liver disease and stroke

People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.

10 Jan 2011

Carrots and plums for better looks!

Researchers at St Andrews and Bristol universities have found that carrots and plums could make one more attractive in just two months. They found that these fruits and vegetables contain pigments called carotenoids that color the skin within two months making a person more attractive and healthy.

9 Jan 2011

Vaccines for alcoholism and cocaine addiction coming soon

In a latest development, researchers from Chile have come up with a vaccine to cure alcoholics. It will help them kick the habit by creating a sensation of a terrible hangover after just a few drinks. The mechanism by which this vaccine acts is by neutralizing a group of enzymes that help the body to break down alcohol. When the enzymes aldehyde dehydrogenase is disabled the body accumulates the alcohol to create the hangovers after just a few drinks.

9 Jan 2011

Secret behind viruses making covert attacks unravelled: Study

Some viruses use a form of disguise to avoid being detected by the body’s immune system. Now researchers from Melbourne have found out the secret behind the Trojan-horse like phenomenon. Gabrielle Belz and her colleagues at Parkville’s Walter and Eliza Hall Institute in collaboration with researchers from the University of Cambridge found the key viral gene that was responsible for the phenomenon called K3. The study appeared in the current issue of the Journal of Immunology.

9 Jan 2011

Green tea may help in Alzheimer’s disease: Study

A new study finds that a cup of green tea may protect against Alzheimer’s disease and other forms of dementia. The researchers looked at the effects of a concentrated green tea extract that had been treated in the laboratory to mimic the effects of normal digestion.

9 Jan 2011

Simple Alzheimer’s disease test developed

The latest research has shown that a simple blood test could detect Alzheimer’s disease. Applying the same technology it could also detect hard-to-detect cancers and other diseases. The study reports appeared this Thursday in the journal Cell.

9 Jan 2011

Sutro, Pfizer enter multi-year collaboration for novel peptide-based therapeutics

Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

7 Jan 2011

MMRF awards $3 million under 2010 Biotech Investment Awards program

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

7 Jan 2011

Study finds combined treatments safe and effective for severe acute pancreatitis

The use of combined treatments for severe acute pancreatitis is safe and effective in managing the disease, resulting in shorter hospitalizations and fewer radiological procedures than standard therapy, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. In a related study, doctors found that patients with infected pancreatic necrosis were able to avoid surgery through primary conservative treatment, which is in-patient medical treatment.

7 Jan 2011

Elevated rates of 'Sarcoid Like' Granulomatous Pulmonary Disease found in WTC responders

Mount Sinai researchers coordinating the largest clinical study to date of "Sarcoid Like" Granulomatous Pulmonary Disease in World Trade Center (WTC) responders have found that the rate of the condition was increased in this group as compared to the records of pre-9/11 FDNY personnel. The study is published online in the American Journal of Industrial Medicine.

7 Jan 2011

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas), for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV).

7 Jan 2011